Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS-UC: Tulisokibart in Moderately to Severely Active Ulcerative Colitis
NCT04996797Phase 2Completed
- Sponsor
- Prometheus Biosciences
- Start
- Jul 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of tulisokibart in ulcerative colitis (UC), sponsored by Prometheus Biosciences. Started Jul 2021; status: completed.
02
Drugs
tulisokibart
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04996797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04996797.